Phaseline

Companies › Eagle Pharmaceuticals

Eagle Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CAL02
Liposomal bacterial virulence neutralizer
–Phase 2Pneumonia, Bacterial–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05776004CAL02Phase 2Pneumonia, BacterialInfectious diseaseFeb 2026

From the company's SEC filings

Complete response letters from FDA

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Vasomune Therapeutics Altesa Biosciences Code Pharma Peptilogics AVVA Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.